SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results topped expectations and marked its first profit since its IPO, with rapid growth in its AI-compute business and plans for heavy infrastructure spending driving attention. Many traders welcomed the growth and outlook, while others questioned the valuation, spending and share-unlock risk; discussion of a possible Tesla merger added speculation, but no deal is assured.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary first-quarter update sharply raised its revenue and gross-margin outlook, citing stronger AI-platform demand, sparking a surge in shares. Traders largely welcomed the update as evidence of robust AI-server demand and anticipated short covering, while some questioned whether the gains would hold given the companys execution and credibility concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, slowing revenue growth and a reduced advertising outlook, prompting a sharp selloff. Traders are debating whether the drop reflects worsening growth prospects or an overreaction to the outlook, with some pointing to continued profitability as a reason to buy the dip.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas rebound is drawing attention amid confirmed formation of special committees to explore a potential SpaceX merger, though Musk said a deal is uncertain and would require shareholder support. Traders are split between enthusiasm over possible synergies and skepticism about the terms and timing, while positioning around Teslas Q3 earnings adds volatility.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Q3 earnings expectations dominate, with traders debating whether results and guidance can support Bloom Energys premium valuation after a sharp pullback. Bulls point to fuel-cell demand from AI data centers, while skeptics cite valuation risk and broader weakness in AI-related stocks.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is being swept up in a sharp memory-chip and Korean-market selloff, with traders citing KOSPI weakness, foreign selling, and fears about Chinese competition and the durability of the AI-driven memory cycle. Bulls argue the decline is excessive given strong memory demand and low valuations, while bears see further downside risk from cyclical and oversupply concerns.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads sharp rally is driven mainly by its agreement to sell its prenatal testing business to Labcorp for $210 million in cash plus inventory value, which traders view as a major cash infusion and a shift toward oncology. Bulls see the deal as a balance-sheet and strategic positive, while skeptics argue that selling a revenue-generating unit leaves a smaller business with ongoing debt and execution concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDA accepted CorMedixs REZZAYO filing for priority review for prevention of invasive fungal disease, with a target decision in Q1 2027; traders see the potential label expansion as a major growth opportunity but note that approval is not assured. The community is divided between optimism about the expanded use and frustration that the news has had little effect on the share price, alongside continuing concerns about DefenCaths reimbursement and adoption.

Braze, Inc. operates a customer relationship management platform for mobile applications. Its application combines messaging, audience segmentation, analytics and user support in a single integrated solution. The firm offers push notifications, email, in-app messages, and news feed services. The company was founded by Mark Ghermezian, William Magnuson, and Jonathan Hyman on March 28, 2011 and is headquartered in New York, NY.

Braze Inc - Ordinary Shares - Class A

Braze Inc

Salesforces all-cash agreement to acquire Braze at a substantial premium drove the sharp share-price jump. Traders celebrated the buyout while debating the remaining merger-arbitrage spread and lengthy closing process, with some also weighing analyst downgrades and concerns about the deal valuation.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, prompting a burst of bullish interest. Traders are divided over whether the efficacy is strong enough to outweigh concerns about agitation and higher treatment discontinuations, with the initial rally fading amid profit-taking and short-selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication 

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.

Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder

RHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

Anika Therapeutics, Inc. engages in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

Anika Therapeutics Inc.

These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright raised CORT’s price target to $165 from $95 and maintained a ‘Buy’ rating, according to The Fly.</li><li>Corcept reported second-quarter revenue of $256.1 million, up 32% year over year.</li><li>B. Riley raised ANIK’s price target and maintained a ‘Buy’ rating, citing improved margins and structural cost improvements that could support long-term profitability.</li></ul>Corcept Therapeutics (CORT) and Anika Therapeutics (ANIK) hit fresh 52-week highs on Thursday, with CORT recording its biggest single-day gains in nearly 16 months, following price target hikes on Wall Street after a better-than-expected second-quarter print.At the time of writing, <a href="https://stocktwits.com/symbol/CORT">CORT stock</a> was up 27% while <a href="https://stocktwits.com/symbol/ANIK">ANIK shares</a> gained 13%.<h2 class="st-heading-2">Wall Street Sees 40% Upside Potential In CORT Stock After Q2 Earnings Beat</h2>Corcept Therapeutics received major Wall Street support after reporting strong second-quarter results and sharply raising its 2026 outlook. H.C. Wainwright raised its price target to $165 from $95 and maintained a ‘Buy’ rating, according to The Fly. The firm said Corcept has evolved into a multi-product company with its expansion into oncology.Piper Sandler also lifted its target to $165 from $88 and kept an ‘Overweight’ rating. The price targets imply a 40% upside potential from current levels.Corcept reported revenue of $256.1 million, up 32% year over year and above analysts’ expectations of $221.2 million, according to Fiscal.ai.&nbsp;Earnings came in at $0.36 per share, significantly ahead of the $0.02 estimate.Korlym and its authorized generic drug to treat Cushing’s syndrome generated $208.6 million in revenue, while ovarian cancer treatment Lifyorli contributed $47.6 million. The company also increased its 2026 revenue guidance to $1.1 billion to $1.2 billion, up from $950 million to $1.05 billion previously.Retail sentiment surrounding CORT on Stocktwits&nbsp;flipped to ‘extremely bullish’ from ‘neutral’ a day earlier, amid a 5,300% increase in message volumes. The stock has soared more than 210% so far this year.<h2 class="st-heading-2">B. Riley Sees Long-Term Profitability Prospects For ANIK</h2>Anika Therapeutics received price-target hikes after reporting stronger-than-expected second-quarter results and raising its 2026 outlook.B. Riley raised its price target to $21 from $18 and maintained a ‘Buy’ rating, citing improved margins, commercial growth, and structural cost improvements that could support long-term profitability.Barrington also lifted its target to $21 from $17 and kept an ‘Outperform’ rating, pointing to the quarterly earnings beat, higher full-year guidance, and strong international momentum.On Wednesday, Anika reported second-quarter revenue of $32.6 million, up from $28.2 million a year earlier and ahead of analysts’ $29.2 million estimate, according to Fiscal.ai. The company earned $0.42 per share, comfortably beating the $0.03 consensus estimate. Anika also raised its 2026 revenue growth guidance to 5% to 10%, up from the previous 1% to 9% range.Retail sentiment surrounding ANIK on Stocktwits remained in the ‘bearish’ territory over the past 24 hours, amid ‘high’ message volumes. The stock has surged more than 95% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-launches-shelf-obesity-drug-study-q2-results/cZN5etIRJcz">VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corcept Therapeutics logo is seen displayed on the screen of a tablet

Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook.

Corcept Therapeutics Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$20.44
Prev Close	$20.22
Open	$20.22
Dividend Yield	0.00%
50-Day Moving Average	$20.69
Beta	0.88
Avg. Volume	78,071.59
PE Ratio	-74.60

52-Week High	$22.88
52-Week Low	$9.01
Market Capitalization	$270.6M
EPS (Annual)	-$0.7588
Price to Book	1.99
Revenue Per Employee	$480,080.85

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANIK Fundamentals